Subgroup analysis of core-binding factor AML (CBF-AML) (n=37), the most prevalent molecular subtype, demonstrated no significant differences in EFS, OS, or CIR between groups when analyzing all patients with CBF-AML (EFS: 100% vs. 87.8%, HR, 0.240, 95% CI, 0.020–2.859, p = 0.259; OS: 100% vs. 95.7% ± 4.3%, HR, 0.260, 95% CI, 0.003–22.910, p = 0.555; CIR: 0% vs. 12.3%, HR, 0.240, 95% CI, 0.020–2.859, p = 0.259) (Figure 4A–C). This evidence concerns the gene CEBPZ and acute myeloid leukemia.